Skip to content
Home
Karl D. Kieburtz, M.D., M.P.H.

Karl D. Kieburtz, M.D., M.P.H.

About Me

Karl Kieburtz, MD, MPH, is the Robert J. Joynt Professor in Neurology, Senior Associate Dean for Clinical Research and Director of the Clinical & Translational Science Institute at the University of Rochester Medical Center. He is also Professor of Public Health Sciences and of Environmental Medicin...
Karl Kieburtz, MD, MPH, is the Robert J. Joynt Professor in Neurology, Senior Associate Dean for Clinical Research and Director of the Clinical & Translational Science Institute at the University of Rochester Medical Center. He is also Professor of Public Health Sciences and of Environmental Medicine, and was the founding Director of the Center for Human Experimental Therapeutics (CHET). CHET conducts learning phase clinical trials in a wide spectrum of disorders in collaboration with investigators within the URMC as well as with colleagues throughout North America, Europe, Asia and Oceania. Dr Kieburtz's primary clinical and research interests are neurodegenerative diseases affecting the basal ganglia, particularly Parkinson disease, Huntington disease, and HIV related neurologic disorders. He is the principal investigator for the NINDS sponsored trials of neuroprotective agents for PD (NET-PD) and directed the Coordination Center for an NEI-funded consortium in Neuro-opthalmology. He completed his MD and MPH degrees at the University of Rochester, as well as his Neurology residency and a fellowship in Experimental Therapeutics.

Faculty Appointments

Professor (Part-Time) - Department of Neurology, Center for Health and Technology (SMD)

Credentials

Education

MD | Univ Rochester Sch Med/Dent. Medicine. 1985

M.P.H. | University of Rochester. 1985

BA | Amherst College. Neuroscience and Religion. 1980

Awards

HONORS:
Phi Beta Kappa, Amherst College, 1980;
Frank Dow Award in Chemistry, Amherst College, 1980;
Logan Clendenning Fellowship in the History of Medicine, 1982;
George W. Merck Dean's Teaching Scholar, University of Rochester School of Medicine 1994-1997;
The Best Doctors in America, Woodward/White, Inc., 2nd edition, 1994

Deprenyl and Tocopherol Antioxidant Therapy of Parkinsonism (DATATOP) NS24778.

Dideoxyinosine treatment of AIDS Dementia.

Parkinson Study Group START Clinical Trials.

AIDS Clinical Trial Group.

Parkinson Study Group ROADS Clinical Trial.

BLIND-DATE Clinical Trial.

Glutamate Antagonist Tolerability in Huntington's Disease.

STEP-UP Clinical Trial.

European Network for Striatal Transplantation in Huntington's Disease(NEST-HD):preclinical development & clinical trial method.

Experimental Therapeutics of HIV Neurology (part of Neurologic AIDS Research Consortium Program Project, David Clifford, PI).

SEESAW Clinical Trial.

Dana Foundation Consortium For The Treatment of HIV Dementia And Related Disorders.

A Double Blind Study of Amitriptyline and Mexilitine for Painful HIV Neuropathy.

Clozapine for Psychosis in PD.

Investigation of Tolerability of OPC-14117 in Huntington's Disease.

Trial of a Glutamate Antagonist in PD and MSA.

Evaluation of SPECT Imaging in The Diagnosis of PD.

Comparison of Levodopa and a Dopamine Agonist in PD.

PSG PRIME: Study of a Dopamine Agonist in Minority Persons.

TACT Study: Treatment of ADHD in Children with Tourette's.

PSG SPIRAL Study: Interaction Study of Remacemide and Levodopa in Parkinson's Disease.

Clinical Trials Unit in HIV Dementia.

Co-Enzyme Q10 and Remacemide Evaluation in Huntington's Disease.

Neurocognitive Function, HIV Load and Surrogate Markers (NEAD).

Earlier vs. Later L-dopa in Parkinson's Disease.

Effects of Coenzyme Q10 in Patients With Early, Untreated Parkinson's Disease.

Midcareer Investigator Award in Patient-Oriented Research.

ERSET: A Multi-center Randomized Clinical Trial for Early Treatment of Epilepsy.

Alzheimer's Disease Cooperative Study.

PSG PATCH Study: Topical Dopamine Agonist in PD.

PSG RAPID Study: Monoamine Oxidase Inhibitor in PD.

Ethylester of Levodopa in PD.

Early Randomized Surgical Epilepsy Trial.

Targeted Neuroprotection for HIV-1 Associated Neurologic Disease.

Neuroprotection Studies in PD: A Coordinating Center.

Neurobiological Predictors of Huntington's Disease (PREDICT-HD).

Prospective Huntington At-Risk Observational Study (PHAROS).

Prospective Huntington At-Risk Observational Study (PHAROS).

HSG Trend Study: A multicenter placebo-controlled efficacy and safety trial of an experimental membrane-stabilizing drug.

HSG DOMINO Study: Double blind study of minocycline in Huntington's disease.

Multi-Center Phase 1-2A Open-Label Dose-Escalation & Randomized, Double-Blind, Placebo-controlled Study of Dimebon in Subjects.

PSG Prami BID Study: A randomized, double-blind, active and placebo controlled, efficacy study of pramipexole in subjects w/ PD.

The University of Rochester's Clinical and Translational Science Institute.

Neuroprotection Studies in PD: A Coordinating Center.

Midcareer Investigator Award in Patient-Oriented Research.

Data Coordination and Biostatistics Center for the NORDIC Network.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate.

A multi-center, N.A., randomized, double-blind, parallel group study comparing three doses of ACR16... (HART).

Inosine for Parkinson's Disease: Safety and Trial Design Optimization.

Coordination and Statistics for CoQ10 in HD (2CARE).

Prophylactic Phenobarbital after Resolution of Neonatal Seizures (PROPHENO).

Ethics of Sham Surgery Controls to Test Novel Parkinson's Disease Interventions.

PSG PRECEPT study, CEP1347 in Early PD.

Research

Dr. Karl Kieburtz MD MPH is the Robert J Joynt Professor in Neurology and the Director of the Clinical & Translational Science Institute and Senior Associate Dean for Clinical Research at the University of Rochester School of Medicine and Dentistry in Rochester, NY. He also has appointments as Profe...
Dr. Karl Kieburtz MD MPH is the Robert J Joynt Professor in Neurology and the Director of the Clinical & Translational Science Institute and Senior Associate Dean for Clinical Research at the University of Rochester School of Medicine and Dentistry in Rochester, NY. He also has appointments as Professor of Environmental Medicine and of Public Health Sciences. His research career has focused on developing treatments for diseases with high unmet therapeutic needs, including HIV-related neurologic syndromes and neurodegenerative disorders, such as Alzheimer and Parkinson disease. His research program has had continuous independent funding from the National Institutes of Health for over 20 years and he has served as the principal investigator on over two dozen multi-center clinical trials. He has served as a consultant to United States government through the FDA (serving on and chairing the Peripheral and Central Nervous System Advisory Committee), Veterans Administration (chairing the Scientific Evaluation Committee for the Cooperative Studies Program) and the National Institute of Neurologic Disorders and Stroke (serving on the clinical trials study section). He has served as an officer or board member for multiple international professional organizations including the American Neurological Association, the American Society for Experimental Therapeutics and the Movement Disorders Society, and has served as Associate Editor of the journals Neurology and Movement Disorders. As the Director Clinical & Translational Science Institute he helps institutional investigators translate their clinical and bench-based research findings into potential human therapeutic agents. For his roles as an educator he has received the University of Rochester Medical Center's highest mentoring awards as well as a K24 award from the NIH for mentoring junior faculty. He also maintains an active clinical practice in neurology, primarily seeing patients with neurodegenerative disorders.

Publications

Journal Articles

CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.

Brice NL, Carlton M, Margolin DH, Bexon M, Matthews KL, Dawson LA, Ellenbogen AL, Olanow CW, Dubow J, Kieburtz K

EClinicalMedicine.. 2024 November 77 :102882. Epub 10/18/2024.

Ira Shoulson, MD (1946-2024).

Dorsey ER, Holloway RG, Kieburtz K, Griggs RC

Neurology.. 2024 October 22103 (8):e209892. Epub 09/19/2024.

Eleven Years of Change: Disease Progression in Biomarker-Defined Sporadic Parkinson's Disease.

Gonzalez-Latapi P, Gochanour C, Cho H, Ho Choi S, Caspell-Garcia C, Coffey C, Brumm M, Lafontant DE, Xiao Y, Tanner C, Venuto CS, Kieburtz K, Chahine LM, Poston KL, Siderowf A, Marek K, Simuni T

medRxiv : the preprint server for health sciences.. 2024 October 10 Epub 10/10/2024.

Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts.

Dam T, Pagano G, Brumm MC, Gochanour C, Poston KL, Weintraub D, Chahine LM, Coffey C, Tanner CM, Kopil CM, Xiao Y, Chowdhury S, Concha-Marambio L, DiBiaso P, Foroud T, Frasier M, Jennings D, Kieburtz K, Merchant K, Mollenhauer B, Montine TJ, Nudelman K, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tolosa E, Siderowf A, Dunn B, Simuni T, Marek K,

NPJ Parkinson's disease.. 2024 September 2710 (1):178. Epub 09/27/2024.

Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts.

Dam T, Pagano G, Brumm MC, Gochanour C, Poston KL, Weintraub D, Chahine LM, Coffey C, Tanner CM, Kopil CM, Xiao Y, Chowdhury S, Concha-Marambio L, DiBiaso P, Foroud T, Frasier M, Jennings D, Kieburtz K, Merchant K, Mollenhauer B, Montine TJ, Nudelman K, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tolosa E, Siderowf A, Dunn B, Simuni T, Marek K,

medRxiv : the preprint server for health sciences.. 2024 September 10 Epub 09/10/2024.

Predicting Cerebrospinal Fluid Alpha-Synuclein Seed Amplification Assay Status from Demographics and Clinical Data.

Venuto CS, Herbst K, Chahine LM, Kieburtz K

medRxiv : the preprint server for health sciences.. 2024 August 8 Epub 08/08/2024.

LRRK2-Associated Parkinsonism With and Without Evidence of Alpha-Synuclein Aggregates.

Chahine LM, Lafontant DE, Choi SH, Iwaki H, Blauwendraat C, Singleton AB, Brumm MC, Alcalay RN, Merchant K, Nudelman KNH, Dagher A, Vo A, Tao Q, Venuto CS, Kieburtz K, Poston KL, Bressman S, Gonzalez-Latapi P, Avants B, Coffey C, Jennings D, Tolosa E, Siderowf A, Marek K, Simuni T

medRxiv : the preprint server for health sciences.. 2024 July 22 Epub 07/22/2024.

Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study.

Olanow CW, McIntyre D, Matarazzo M, Leinonen M, McGarry A, Kamp C, Kennedy J, Torti M, Kruger R, Obeso JA, Stocchi F, Heller E, Kieburtz K

Movement disorders : official journal of the Movement Disorder Society.. 2024 June 39 (6):945-954. Epub 05/02/2024.

Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.

Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vara J, Isaacson SH, Kieburtz K, LeWitt PA, Lopez-Manzanares L, Olanow CW, Poewe W, Sarva H, Yardeni T, Adar L, Salin L, Lopes N, Sasson N, Case R, Rascol O,

The Lancet. Neurology.. 2024 May 23 (5):465-476. Epub 03/15/2024.

Dry-Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation.

Dorsey ER, Kinel D, Pawlik ME, Zafar M, Lettenberger SE, Coffey M, Auinger P, Hylton KL, Shaw CW, Adams JL, Barbano R, Braun MK, Schwarz HB, Lawrence BP, Kieburtz K, Tanner CM, de Miranda BR, Goldman SM

Movement disorders : official journal of the Movement Disorder Society.. 2024 March 39 (3):606-613. Epub 02/23/2024.

Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.

Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M,

Nature medicine.. 2024 February 30 (2):606. Epub 1900 01 01.

A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.

Olanow CW, Hauser RA, Burdick DJ, Dhall R, de Marcaida JA, Gil RA, Kreitzman DL, Elmer LW, McGarry A, Kieburtz K,

Movement disorders : official journal of the Movement Disorder Society.. 2024 February 39 (2):350-359. Epub 10/27/2023.

A biological definition of neuronal ?-synuclein disease: towards an integrated staging system for research.

Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, DiBiaso P, Foroud T, Frasier M, Gochanour C, Jennings D, Kieburtz K, Kopil CM, Merchant K, Mollenhauer B, Montine T, Nudelman K, Pagano G, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tanner CM, Tolosa E, Weintraub D, Xiao Y, Siderowf A, Dunn B, Marek K

The Lancet. Neurology.. 2024 February 23 (2):178-190. Epub 1900 01 01.

Evaluation of ATN Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.

Cousins KAQ, Irwin DJ, Tropea TF, Rhodes E, Phillips J, Chen-Plotkin AS, Brumm MC, Coffey CS, Kang JH, Simuni T, Foroud TM, Toga AW, Tanner CM, Kieburtz KD, Mollenhauer B, Galasko D, Hutten S, Weintraub D, Siderowf AD, Marek K, Poston KL, Shaw LM,

Neurology.. 2024 February 102 (4):e208033. Epub 02/02/2024.

Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Klos K, Bordelon Y, St Hiliare MH, Shprecher D, Lee S, Dawson TM, Roschke V, Kieburtz K

The Lancet. Neurology.. 2024 January 23 (1):37-45. Epub 1900 01 01.

Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.

Wyse RK, Isaacs T, Barker RA, Cookson MR, Dawson TM, Devos D, Dexter DT, Duffen J, Federoff H, Fiske B, Foltynie T, Fox S, Greenamyre JT, Kieburtz K, Kordower JH, Krainc D, Matthews H, Moore DJ, Mursaleen L, Schwarzschild MA, Stott SRW, Sulzer D, Svenningsson P, Tanner CM, Carroll C, Simon DK, Brundin P

Journal of Parkinson's disease.. 2024 14 (4):657-666. Epub 1900 01 01.

Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design.

Venuto CS, Smith G, Herbst K, Zielinski R, Yung NCW, Grosset DG, Dorsey ER, Kieburtz K

Movement disorders : official journal of the Movement Disorder Society.. 2023 October 38 (10):1774-1785. Epub 06/26/2023.

Transdermal Nicotine Treatment and Progression of Early Parkinson's Disease.

Oertel WH, Müller HH, Unger MM, Schade-Brittinger C, Balthasar K, Articus K, Brinkman M, Venuto CS, Tracik F, Eberling J, Eggert KM, Kamp C, Kieburtz K, Boyd JT

NEJM evidence.. 2023 September 2 (9):EVIDoa2200311. Epub 08/22/2023.

Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study.

Weintraub D, Picillo M, Cho HR, Caspell-Garcia C, Blauwendraat C, Brown EG, Chahine LM, Coffey CS, Dobkin RD, Foroud T, Galasko D, Kieburtz K, Marek K, Merchant K, Mollenhauer B, Poston KL, Simuni T, Siderowf A, Singleton A, Seibyl J, Tanner CM,

Movement disorders clinical practice.. 2023 June 10 (6):943-955. Epub 04/25/2023.

Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using ?-synuclein seed amplification: a cross-sectional study.

Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, Galasko D, Kieburtz K, Merchant K, Mollenhauer B, Poston KL, Seibyl J, Simuni T, Tanner CM, Weintraub D, Videnovic A, Choi SH, Kurth R, Caspell-Garcia C, Coffey CS, Frasier M, Oliveira LMA, Hutten SJ, Sherer T, Marek K, Soto C,

The Lancet. Neurology.. 2023 May 22 (5):407-417. Epub 1900 01 01.

Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa.

LeWitt P, Liang GS, Olanow CW, Kieburtz KD, Jimenez R, Olson K, Klepitskaya O, Loewen G

Clinical neuropharmacology.. 2023 46 (2):43-50. Epub 01/21/2023.

Adaptive clinical trials and master protocols.

McGarry A, Kieburtz K

Handbook of clinical neurology.. 2023 193 :313-323. Epub 1900 01 01.

Trichloroethylene: An Invisible Cause of Parkinson's Disease?

Dorsey ER, Zafar M, Lettenberger SE, Pawlik ME, Kinel D, Frissen M, Schneider RB, Kieburtz K, Tanner CM, De Miranda BR, Goldman SM, Bloem BR

Journal of Parkinson's disease.. 2023 13 (2):203-218. Epub 1900 01 01.

Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression.

Brumm MC, Siderowf A, Simuni T, Burghardt E, Choi SH, Caspell-Garcia C, Chahine LM, Mollenhauer B, Foroud T, Galasko D, Merchant K, Arnedo V, Hutten SJ, O'Grady AN, Poston KL, Tanner CM, Weintraub D, Kieburtz K, Marek K, Coffey CS,

Journal of Parkinson's disease.. 2023 13 (6):899-916. Epub 1900 01 01.

Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.

Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M,

Nature medicine.. 2022 October 28 (10):2183-2193. Epub 08/08/2022.

Prevalence and Incidence of Nonmotor Symptoms in Individuals with and Without Parkinson's Disease.

Paracha M, Herbst K, Kieburtz K, Venuto CS

Movement disorders clinical practice.. 2022 October 9 (7):961-966. Epub 08/18/2022.

Monitoring gait at home with radio waves in Parkinson's disease: A marker of severity, progression, and medication response.

Liu Y, Zhang G, Tarolli CG, Hristov R, Jensen-Roberts S, Waddell EM, Myers TL, Pawlik ME, Soto JM, Wilson RM, Yang Y, Nordahl T, Lizarraga KJ, Adams JL, Schneider RB, Kieburtz K, Ellis T, Dorsey ER, Katabi D

Science translational medicine.. 2022 September 2114 (663):eadc9669. Epub 09/21/2022.

Quantifying Patient Investment in Novel Neurological Drug Development.

MacPherson A, Gumnit E, Ouimet C, Hutchinson N, Kieburtz K, Pearson TS, Kimmelman J

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.. 2022 September 19 (5):1507-1513. Epub 06/28/2022.

Remote smartphone monitoring of Parkinson's disease and individual response to therapy.

Omberg L, Chaibub Neto E, Perumal TM, Pratap A, Tediarjo A, Adams J, Bloem BR, Bot BM, Elson M, Goldman SM, Kellen MR, Kieburtz K, Klein A, Little MA, Schneider R, Suver C, Tarolli C, Tanner CM, Trister AD, Wilbanks J, Dorsey ER, Mangravite LM

Nature biotechnology.. 2022 April 40 (4):480-487. Epub 08/09/2021.

Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease.

McGarry A, Auinger P, Kieburtz KD, Bredlau AL, Hersch SM, Rosas HD

Neurology. Clinical practice.. 2022 April 12 (2):131-138. Epub 1900 01 01.

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.

Poewe W, Stocchi F, Arkadir D, Ebersbach G, Ellenbogen AL, Giladi N, Isaacson SH, Kieburtz K, LeWitt P, Olanow CW, Simuni T, Thomas A, Zlotogorski A, Adar L, Case R, Oren S, Fuchs Orenbach S, Rosenfeld O, Sasson N, Yardeni T, Espay AJ,

Movement disorders : official journal of the Movement Disorder Society.. 2021 November 36 (11):2687-2692. Epub 09/08/2021.

Seeking progress in disease modification in Parkinson disease.

Lungu C, Cedarbaum JM, Dawson TM, Dorsey ER, Faraco C, Federoff HJ, Fiske B, Fox R, Goldfine AM, Kieburtz K, Macklin EA, Matthews H, Rafaloff G, Saunders-Pullman R, Schor NF, Schwarzschild MA, Sieber BA, Simuni T, Surmeier DJ, Tamiz A, Werner MH, Wright CB, Wyse R

Parkinsonism & related disorders.. 2021 September 90 :134-141. Epub 09/10/2021.

The triple aim of clinical research.

Dorsey ER, Kieburtz K

Clinical trials : journal of the Society for Clinical Trials.. 2021 August 18 (4):511-513. Epub 04/20/2021.

Parkinson disease risks: correctly identifying environmental factors for a chronic disease.

Kieburtz K, Dorsey ER

The Journal of clinical investigation.. 2021 June 1131 (11)Epub 1900 01 01.

Reply to: "A New Approach to the Development of Disease-Modifying Therapies for PD".

Kieburtz K, Olanow CW

Movement disorders : official journal of the Movement Disorder Society.. 2021 May 36 (5):1281-1282. Epub 1900 01 01.

A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.

Kieburtz K, Katz R, McGarry A, Olanow CW

Movement disorders : official journal of the Movement Disorder Society.. 2021 January 36 (1):59-63. Epub 10/07/2020.

Dopamine transporter imaging predicts clinically-defined ?-synucleinopathy in REM sleep behavior disorder.

Chahine LM, Brumm MC, Caspell-Garcia C, Oertel W, Mollenhauer B, Amara A, Fernandez-Arcos A, Tolosa E, Simonet C, Hogl B, Videnovic A, Hutten SJ, Tanner C, Weintraub D, Burghardt E, Coffey C, Cho HR, Kieburtz K, Poston KL, Merchant K, Galasko D, Foroud T, Siderowf A, Marek K, Simuni T, Iranzo A

Annals of clinical and translational neurology.. 2021 January 8 (1):201-212. Epub 12/15/2020.

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.

Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H, Schade S, Gera RG, Wang W, Gao F, Frasier M, Chahine LM, Coffey CS, Singleton AB, Simuni T, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Marek K, Siderowf A, Cedarbaum JM, Hutten SJ, Trenkwalder C, Graham D

Movement disorders : official journal of the Movement Disorder Society.. 2020 November 35 (11):1999-2008. Epub 08/15/2020.

BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease.

Fischer DL, Auinger P, Goudreau JL, Cole-Strauss A, Kieburtz K, Elm JJ, Hacker ML, Charles PD, Lipton JW, Pickut BA, Sortwell CE

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.. 2020 October 17 (4):1785-1795. Epub 11/19/2020.

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.

Irwin DJ, Felder J, Coffey CS, Caspell-Garcia C, Kang JH, Simuni T, Foroud T, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Weintraub D, Mollenhauer B, Galasko DR, Siderowf A, Marek K, Trojanowski JQ, Shaw LM,

Annals of neurology.. 2020 September 88 (3):574-587. Epub 07/02/2020.

Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients.

Olanow CW, Standaert DG, Kieburtz K, Viegas TX, Moreadith R

Movement disorders : official journal of the Movement Disorder Society.. 2020 June 35 (6):1055-1061. Epub 04/06/2020.

Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.

Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, Alcalay RN, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Nudelman K, Tosun-Turgut D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Bressman S, Marek K,

Movement disorders : official journal of the Movement Disorder Society.. 2020 May 35 (5):833-844. Epub 02/19/2020.

Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?

Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, Strafella AP, Singleton AB, Barker RA, Kieburtz K, Olanow CW, Lozano A, Kordower JH, Cedarbaum JM, Brundin P, Standaert DG, Lang AE

Neurology.. 2020 March 1794 (11):481-494. Epub 02/26/2020.

Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease.

Feustel AC, MacPherson A, Fergusson DA, Kieburtz K, Kimmelman J

Neurology.. 2020 January 794 (1):e1-e14. Epub 12/02/2019.

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.

Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten SJ, Bressman S, Marek K,

The Lancet. Neurology.. 2020 January 19 (1):71-80. Epub 10/31/2019.

Baseline Variables Associated with Functional Decline in 2CARE, A Randomized Clinical Trial in Huntington's Disease.

McGarry A, McDermott MP, Kieburtz K, Peng J, Cudkowicz M,

Journal of Huntington's disease.. 2020 9 (1):47-58. Epub 1900 01 01.

Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson's Disease Parkinson's Progression Markers Initiative Participants.

Javidnia M, Shoulson I, Kieburtz K, Venuto C

Journal of Parkinson's disease.. 2020 10 (3):1239-1243. Epub 1900 01 01.

Deep Phenotyping of Parkinson's Disease.

Dorsey ER, Omberg L, Waddell E, Adams JL, Adams R, Ali MR, Amodeo K, Arky A, Augustine EF, Dinesh K, Hoque ME, Glidden AM, Jensen-Roberts S, Kabelac Z, Katabi D, Kieburtz K, Kinel DR, Little MA, Lizarraga KJ, Myers T, Riggare S, Rosero SZ, Saria S, Schifitto G, Schneider RB, Sharma G, Shoulson I, Stevenson EA, Tarolli CG, Luo J, McDermott MP

Journal of Parkinson's disease.. 2020 10 (3):855-873. Epub 1900 01 01.

Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.

McGarry A, Auinger P, Kieburtz K, Geva M, Mehra M, Abler V, Grachev ID, Gordon MF, Savola JM, Gandhi S, Papapetropoulos S, Hayden M

Journal of Huntington's disease.. 2020 9 (2):173-184. Epub 1900 01 01.

GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop.

Barker RA, Bjorklund A, Gash DM, Whone A, Van Laar A, Kordower JH, Bankiewicz K, Kieburtz K, Saarma M, Booms S, Huttunen HJ, Kells A, Fiandaca MS, Stoessl AJ, Eidelberg D, Federoff H, Voutilainen M, Dexter DT, Eberling J, Brundin P, Isaacs L, Mursaleen L, Bresolin E, Carroll C, Coles A, Fiske B, Matthews H, Lungu C, Wyse RK, Stott S, Lang AE

Journal of Parkinson's disease.. 2020 10 (3):875-891. Epub 1900 01 01.

Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study.

McGarry A, Leinonen M, Kieburtz K, Geva M, Warren Olanow C, Hayden M

Journal of Huntington's disease.. 2020 9 (4):371-380. Epub 1900 01 01.

Longitudinal analyses of cerebrospinal fluid ?-Synuclein in prodromal and early Parkinson's disease.

Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Singleton A, Shaw LM, Trojanowski JQ, Frasier M, Simuni T, Iranzo A, Oertel W, Siderowf A, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Marek K, Galasko D,

Movement disorders : official journal of the Movement Disorder Society.. 2019 September 34 (9):1354-1364. Epub 07/30/2019.

Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).

Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, Frank S, Jennings D, Simuni T

Parkinsonism & related disorders.. 2019 May 62 :201-209. Epub 01/31/2019.

Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial.

McGarry A, McDermott MP, Kieburtz K, Alan Fung WL, McCusker E, Peng J, de Blieck EA, Cudkowicz M,

Neurology.. 2019 April 292 (14):e1643-e1651. Epub 03/08/2019.

Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.

Stocchi F, Heller E, Heller A, Grassini P, Vacca L, Leinonen M, Kieburtz K, Torti M, Warren Olanow C

Movement disorders : official journal of the Movement Disorder Society.. 2019 March 34 (3):425-429. Epub 01/17/2019.

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.

Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB, ,

The Lancet. Neurology.. 2019 February 18 (2):165-176. Epub 12/15/2018.

Sample enrichment for clinical trials to show delay of onset in huntington disease.

Paulsen JS, Lourens S, Kieburtz K, Zhang Y

Movement disorders : official journal of the Movement Disorder Society.. 2019 February 34 (2):274-280. Epub 01/14/2019.

Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures.

Chahine LM, Siderowf A, Barnes J, Seedorff N, Caspell-Garcia C, Simuni T, Coffey CS, Galasko D, Mollenhauer B, Arnedo V, Daegele N, Frasier M, Tanner C, Kieburtz K, Marek K,

Journal of Parkinson's disease.. 2019 9 (4):665-679. Epub 1900 01 01.

The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.

Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun-Turgut D, Poston K, Arnedo V, Frasier M, Sherer T,

Annals of clinical and translational neurology.. 2018 December 5 (12):1460-1477. Epub 10/31/2018.

Adverse event reporting in clinical trials in Parkinson's Disease: Time for change.

Olanow CW, Kenney C, Bandak S, Kieburtz KD

Movement disorders : official journal of the Movement Disorder Society.. 2018 November 33 (11):1685-1687. Epub 11/01/2018.

New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States.

Kieburtz K, Katz R, Olanow CW

Movement disorders : official journal of the Movement Disorder Society.. 2018 July 33 (6):920-927. Epub 12/04/2017.

Huntington's disease: Current and future therapeutic prospects.

Kieburtz K, Reilmann R, Olanow CW

Movement disorders : official journal of the Movement Disorder Society.. 2018 July 33 (7):1033-1041. Epub 05/08/2018.

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.

Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K,

Movement disorders : official journal of the Movement Disorder Society.. 2018 May 33 (5):771-782. Epub 03/23/2018.

Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment.

Litvan I, Kieburtz K, Tröster AI, Aarsland D

Movement disorders : official journal of the Movement Disorder Society.. 2018 April 33 (4):520-527. Epub 03/24/2018.

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.

Simuni T, Caspell-Garcia C, Coffey CS, Weintraub D, Mollenhauer B, Lasch S, Tanner CM, Jennings D, Kieburtz K, Chahine LM, Marek K

Journal of neurology, neurosurgery, and psychiatry.. 2018 January 89 (1):78-88. Epub 10/06/2017.

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.

Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ,

Neurology.. 2017 December 1289 (24):2495-2502. Epub 11/15/2017.

Clinical approaches to the development of a neuroprotective therapy for PD.

Olanow CW, Kieburtz K, Katz R

Experimental neurology.. 2017 December 298 (Pt B):246-251. Epub 06/13/2017.

A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.

Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, Klepiskaya OS, Kreitzman DL, Lew MF, Russell DS, Kadosh S, Litman P, Friedman H, Linvah N, The P B Study Group F

Movement disorders : official journal of the Movement Disorder Society.. 2017 May 32 (5):783-789. Epub 04/03/2017.

Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations.

Hampson NB, Kieburtz KD, LeWitt PA, Leinonen M, Freed MI

The International journal of neuroscience.. 2017 March 127 (3):276-284. Epub 06/27/2016.

Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.

Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE

Movement disorders : official journal of the Movement Disorder Society.. 2017 March 32 (3):319-324. Epub 02/24/2017.

Education and training of clinical and translational study investigators and research coordinators: A competency-based approach.

Calvin-Naylor NA, Jones CT, Wartak MM, Blackwell K, Davis JM, Divecha R, Ellerbeck EF, Kieburtz K, Koziel MJ, Luzuriaga K, Maddox J, Needler NA, Murphy S, Pemberton K, Radovich C, Rubinstein EP, Selker HP, Tenaerts P, Unsworth K, Wilson K, Wright JE, Barohn R, Shanley TP

Journal of clinical and translational science.. 2017 February 1 (1):16-25. Epub 01/13/2017.

Enhancing Clinical Research Professionals' Training and Qualifications (ECRPTQ): Recommendations for Good Clinical Practice (GCP) training for investigators and study coordinators.

Shanley TP, Calvin-Naylor NA, Divecha R, Wartak MM, Blackwell K, Davis JM, Ellerbeck EF, Kieburtz K, Koziel MJ, Luzuriaga K, Maddox J, Needler NA, Murphy S, Pemberton K, Radovich C, Rubinstein EP, Selker HP, Tenaerts P, Unsworth K, Wilson K, Wright JE, Barohn R

Journal of clinical and translational science.. 2017 February 1 (1):8-15. Epub 01/13/2017.

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M,

Neurology.. 2017 January 1088 (2):152-159. Epub 12/02/2016.

Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.

Hauser RA, Li R, Pérez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC,

Journal of Parkinson's disease.. 2017 7 (1):117-127. Epub 1900 01 01.

Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.

McGarry A, Kieburtz K, Abler V, Grachev ID, Gandhi S, Auinger P, Papapetropoulos S, Hayden M

Journal of Huntington's disease.. 2017 6 (3):189-199. Epub 1900 01 01.

The First Frontier: Digital Biomarkers for Neurodegenerative Disorders.

Dorsey ER, Papapetropoulos S, Xiong M, Kieburtz K

Digital biomarkers.. 2017 1 (1):6-13. Epub 07/04/2017.

Communicating with participants during the conduct of multi-center clinical trials.

Augustine EF, Dorsey ER, Hauser RA, Elm JJ, Tilley BC, Kieburtz KK

Clinical trials : journal of the Society for Clinical Trials.. 2016 December 13 (6):592-596. Epub 08/29/2016.

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.

LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire MH, Ellenbogen A, Leinonen M, Hampson NB, DeFeo-Fraulini T, Freed MI, Kieburtz KD

Movement disorders : official journal of the Movement Disorder Society.. 2016 September 31 (9):1356-65. Epub 04/19/2016.

Moving Parkinson care to the home.

Dorsey ER, Vlaanderen FP, Engelen LJ, Kieburtz K, Zhu W, Biglan KM, Faber MJ, Bloem BR

Movement disorders : official journal of the Movement Disorder Society.. 2016 September 31 (9):1258-62. Epub 08/08/2016.

Are patients with amyotrophic lateral sclerosis at risk of a therapeutic misconception?

Kim SY, Wilson R, De Vries R, Ryan KA, Holloway RG, Kieburtz K

Journal of medical ethics.. 2016 August 42 (8):514-8. Epub 03/10/2016.

Understanding the 'therapeutic misconception' from the research participant's perspective.

Kim SY, De Vries R, Holloway RG, Kieburtz K

Journal of medical ethics.. 2016 August 42 (8):522-3. Epub 05/04/2016.

A review of disease progression models of Parkinson's disease and applications in clinical trials.

Venuto CS, Potter NB, Ray Dorsey E, Kieburtz K

Movement disorders : official journal of the Movement Disorder Society.. 2016 July 31 (7):947-956. Epub 05/26/2016.

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease.

Simuni T, Long JD, Caspell-Garcia C, Coffey CS, Lasch S, Tanner CM, Jennings D, Kieburtz KD, Marek K,

Annals of clinical and translational neurology.. 2016 July 3 (7):482-94. Epub 05/17/2016.

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM,

Acta neuropathologica.. 2016 June 131 (6):935-49. Epub 03/28/2016.

Treating neurodegenerative disease before illness: a challenge for the 21st century.

Kieburtz K

The Lancet. Neurology.. 2016 May 15 (6):540-1. Epub 03/21/2016.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C

JAMA neurology.. 2016 January 73 (1):102-10. Epub 1900 01 01.

CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes.

Selker HP, Buse JB, Califf RM, Carter R, Cooper DM, Davis J, Ford DE, Galassetti P, Guay-Woodford L, Huggins GS, Kasper A, Kieburtz K, Kirby A, Klein AK, Kline J, O' Neill RT, Rape M, Reichgott DJ, Rojevsky S, Rosenthal GE, Rubinstein EP, Shepherd A, Stacy M, Terrin N, Wallace M, Welch L

Clinical and translational science.. 2015 December 8 (6):623-31. Epub 07/16/2015.

Advances in clinical trials for movement disorders.

Kieburtz K, Olanow CW

Movement disorders : official journal of the Movement Disorder Society.. 2015 September 1530 (11):1580-7. Epub 08/26/2015.

"It is not guaranteed that you will benefit": True but misleading?

Kim SY, Wilson R, De Vries R, Kim HM, Holloway RG, Kieburtz K

Clinical trials : journal of the Society for Clinical Trials.. 2015 August 12 (4):424-9. Epub 05/11/2015.

Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception?

Kim SY, De Vries R, Parnami S, Wilson R, Kim HM, Frank S, Holloway RG, Kieburtz K

Journal of medical ethics.. 2015 May 41 (5):391-7. Epub 05/22/2014.

Novel methods and technologies for 21st-century clinical trials: a review.

Dorsey ER, Venuto C, Venkataraman V, Harris DA, Kieburtz K

JAMA neurology.. 2015 May 72 (5):582-8. Epub 1900 01 01.

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM

JAMA.. 2015 February 10313 (6):584-93. Epub 1900 01 01.

Could the High Prevalence of Therapeutic Misconception Partly Be a Measurement Problem?

Kim SY, Wilson R, De Vries R, Kim HM, Holloway RG, Kieburtz K

IRB.. 2015 37 (4):11-8. Epub 1900 01 01.

Pooled analysis of phase III with entacapone in Parkinson's disease.

Kuoppamäki M, Vahteristo M, Ellmén J, Kieburtz K

Acta neurologica Scandinavica.. 2014 October 130 (4):239-47. Epub 09/03/2014.

Treating idiopathic intracranial hypertension--reply.

Wall M, McDermott MP, Kieburtz KD, Kupersmith MJ

JAMA neurology.. 2014 October 71 (10):1327-8. Epub 1900 01 01.

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.

Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S

The Lancet. Neurology.. 2014 August 13 (8):767-76. Epub 07/06/2014.

The idiopathic intracranial hypertension treatment trial: design considerations and methods.

Friedman DI, McDermott MP, Kieburtz K, Kupersmith M, Stoutenburg A, Keltner JL, Feldon SE, Schron E, Corbett JJ, Wall M,

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.. 2014 June 34 (2):107-17. Epub 1900 01 01.

The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.

Wall M, Kupersmith MJ, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, McDermott MP,

JAMA neurology.. 2014 June 71 (6):693-701. Epub 1900 01 01.

A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study.

Tanner CM, Meng CC, Ravina B, Lang A, Kurlan R, Marek K, Oakes D, Seibyl J, Flagg E, Gauger L, Guest DD, Goetz CG, Kieburtz K, DiEuliis D, Fahn S, Elliott RA, Shoulson I

Movement disorders : official journal of the Movement Disorder Society.. 2014 May 29 (6):743-9. Epub 02/11/2014.

Results of the citalopram to enhance cognition in Huntington disease trial.

Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Jorge R, Biglan K, Caviness J, Olson B, Robinson RG, Kieburtz K, Paulsen JS

Movement disorders : official journal of the Movement Disorder Society.. 2014 March 29 (3):401-5. Epub 12/27/2013.

Initiating levodopa therapy for Parkinson's disease.

Olanow CW, Kieburtz K, Stocchi F

Movement disorders : official journal of the Movement Disorder Society.. 2014 March 29 (3):430. Epub 01/09/2014.

Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.

Constantinescu R, Elm J, Auinger P, Sharma S, Augustine EF, Khadim L, Kieburtz K,

Movement disorders : official journal of the Movement Disorder Society.. 2014 February 29 (2):263-5. Epub 12/03/2013.

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A,

The Lancet. Neurology.. 2014 February 13 (2):141-9. Epub 12/20/2013.

Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

, Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K

JAMA neurology.. 2014 February 71 (2):141-50. Epub 1900 01 01.

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R, ,

The New England journal of medicine.. 2014 January 23370 (4):311-21. Epub 1900 01 01.

Designing clinical trials for dystonia.

Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JL, Yeatts SD, Jinnah HA

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.. 2014 January 11 (1):117-27. Epub 1900 01 01.

Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.

, Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, Kupersmith MJ

JAMA.. 2014 311 (16):1641-51. Epub 1900 01 01.

Evidence-based research ethics and determinations of "engagement in research".

Wilson R, Kieburtz K, Holloway RG, Kim SY

IRB.. 2014 36 (2):10-3. Epub 1900 01 01.

Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.

Eberling J, Vincent L, Goldman JG, Weintraub D, Kulisevsky J, Marras C, Stebbins G, Kieburtz K

Journal of Parkinson's disease.. 2014 4 (4):585-9. Epub 1900 01 01.

Association of cerebrospinal fluid ?-amyloid 1-42, T-tau, P-tau181, and ?-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM,

JAMA neurology.. 2013 October 70 (10):1277-87. Epub 1900 01 01.

Robust Bayesian inference for multivariate longitudinal data by using normal/independent distributions.

Luo S, Ma J, Kieburtz KD

Statistics in medicine.. 2013 September 3032 (22):3812-28. Epub 03/11/2013.

A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS, , Siemers E, Sethuraman G, Mohs R,

The New England journal of medicine.. 2013 July 25369 (4):341-50. Epub 1900 01 01.

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.

Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F,

Movement disorders : official journal of the Movement Disorder Society.. 2013 July 28 (8):1064-71. Epub 04/29/2013.

Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments.

Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK

Journal of Parkinson's disease.. 2013 January 13 (3):231-9. Epub 1900 01 01.

Parkinson's disease: evidence for environmental risk factors.

Kieburtz K, Wunderle KB

Movement disorders : official journal of the Movement Disorder Society.. 2013 January 28 (1):8-13. Epub 10/24/2012.

Research participants' "irrational" expectations: common or commonly mismeasured?

Kim SY, de Vries R, Wilson R, Parnami S, Frank S, Kieburtz K, Holloway RG

IRB.. 2013 35 (1):1-9. Epub 1900 01 01.

Sham surgery controls in Parkinson's disease clinical trials: views of participants.

Kim SY, De Vries R, Holloway RG, Wilson R, Parnami S, Kim HM, Frank S, Kieburtz K

Movement disorders : official journal of the Movement Disorder Society.. 2012 September 1527 (11):1461-5. Epub 08/23/2012.

Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations.

Galpern WR, Corrigan-Curay J, Lang AE, Kahn J, Tagle D, Barker RA, Freeman TB, Goetz CG, Kieburtz K, Kim SY, Piantadosi S, Comstock Rick A, Federoff HJ

The Lancet. Neurology.. 2012 July 11 (7):643-50. Epub 1900 01 01.

Comparison of enrollees and decliners of Parkinson disease sham surgery trials.

Kim SY, Wilson RM, Kim HM, Holloway RG, De Vries RG, Frank SA, Kieburtz K

Movement disorders : official journal of the Movement Disorder Society.. 2012 April 27 (4):506-11. Epub 02/07/2012.

Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial.

Engel J, McDermott MP, Wiebe S, Langfitt JT, Stern JM, Dewar S, Sperling MR, Gardiner I, Erba G, Fried I, Jacobs M, Vinters HV, Mintzer S, Kieburtz K,

JAMA.. 2012 March 7307 (9):922-30. Epub 1900 01 01.

Pharmacologic approaches to the treatment of Huntington's disease.

Venuto CS, McGarry A, Ma Q, Kieburtz K

Movement disorders : official journal of the Movement Disorder Society.. 2012 January 27 (1):31-41. Epub 10/13/2011.

TRACK-HD: both promise and disappointment.

Kieburtz K, Venuto C

The Lancet. Neurology.. 2012 January 11 (1):24-5. Epub 12/02/2011.

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

Yerramilli-Rao P, Beal MF, Watanabe D, Kieburtz K, Blieck EA, Kitano M, Hosoe K, Funahashi I, Cudkowicz ME

International journal of toxicology.. 2012 31 (1):58-69. Epub 01/20/2012.

Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10.

Biglan KM, Dorsey ER, Evans RV, Ross CA, Hersch S, Shoulson I, Matson W, Kieburtz K

Journal of Huntington's disease.. 2012 1 (1):65-9. Epub 1900 01 01.

Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease.

Constantinescu R, Romer M, Zetterberg H, Rosengren L, Kieburtz K

Parkinsonism & related disorders.. 2011 November 17 (9):714-5. Epub 07/05/2011.

Milestones in movement disorders clinical trials: advances and landmark studies.

Olanow CW, Wunderle KB, Kieburtz K

Movement disorders : official journal of the Movement Disorder Society.. 2011 May 26 (6):1003-14. Epub 1900 01 01.

Advocacy Recruiting for Huntington's Disease Clinical Trials.

Goodman L, Sia C, Carnes R, Vetter L, Taubman F, Venuto CS, McGarry A, Kieburtz K, Agarwal P

PLoS currents.. 2011 April 123 :RRN1230. Epub 04/12/2011.

Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial.

Kieburtz K,

Movement disorders : official journal of the Movement Disorder Society.. 2011 January 26 (1):37-44. Epub 10/05/2010.

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW

The Lancet. Neurology.. 2010 December 9 (12):1164-1172. Epub 10/20/2010.

Building capacity across the spectrum of research translation: centers of excellence within the Rochester Clinical and Translational Science Institute.

Pearson TA, Fogg TT, Bennett N, Kieburtz K, Kitzman H, Moxley R, Puzas E

Clinical and translational science.. 2010 December 3 (6):272-4. Epub 1900 01 01.

Design considerations for a multicenter randomized controlled trial of early surgery for mesial temporal lobe epilepsy.

Engel J, McDermott MP, Wiebe S, Langfitt JT, Erba G, Gardiner I, Stern J, Dewar S, Sperling MR, Jacobs M, Kieburtz K,

Epilepsia.. 2010 October 51 (10):1978-86. Epub 1900 01 01.

Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.

Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I,

Movement disorders : official journal of the Movement Disorder Society.. 2010 September 1525 (12):1801-8. Epub 1900 01 01.

Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.

, Hyson HC, Kieburtz K, Shoulson I, McDermott M, Ravina B, de Blieck EA, Cudkowicz ME, Ferrante RJ, Como P, Frank S, Zimmerman C, Cudkowicz ME, Ferrante K, Newhall K, Jennings D, Kelsey T, Walker F, Hunt V, Daigneault S, Goldstein M, Weber J, Watts A, Beal MF, Browne SE, Metakis LJ

Movement disorders : official journal of the Movement Disorder Society.. 2010 September 1525 (12):1924-8. Epub 1900 01 01.

Defining disease-modifying therapies for PD--a road map for moving forward.

Olanow CW, Kieburtz K

Movement disorders : official journal of the Movement Disorder Society.. 2010 September 1525 (12):1774-9. Epub 1900 01 01.

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW

Annals of neurology.. 2010 July 68 (1):18-27. Epub 1900 01 01.

Toward more efficient clinical trials for amyotrophic lateral sclerosis.

Cudkowicz ME, Katz J, Moore DH, O'Neill G, Glass JD, Mitsumoto H, Appel S, Ravina B, Kieburtz K, Shoulson I, Kaufmann P, Khan J, Simpson E, Shefner J, Levin B, Cwik V, Schoenfeld D, Aggarwal S, McDermott MP, Miller RG

Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.. 2010 May 311 (3):259-65. Epub 1900 01 01.

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, Factor S, Geschwind MD, Hodgeman K, Kayson E, Noonberg S, Pourfar M, Rabinowitz K, Ravina B, Sanchez-Ramos J, Seely L, Walker F, Feigin A, ,

Archives of neurology.. 2010 February 67 (2):154-60. Epub 1900 01 01.

The relationship between uric acid levels and Huntington's disease progression.

Auinger P, Kieburtz K, McDermott MP

Movement disorders : official journal of the Movement Disorder Society.. 2010 January 3025 (2):224-8. Epub 1900 01 01.

Long term understanding of study information in research participants with Parkinson's disease.

Ravina B, Swearingen C, Elm J, Kamp C, Kieburtz K, Kim SY

Parkinsonism & related disorders.. 2010 January 16 (1):60-3. Epub 06/05/2009.

Discovering neuroprotection in Parkinson's disease, or getting to haphazard.

Kieburtz K

The Mount Sinai journal of medicine, New York.. 2010 77 (6):700-6. Epub 1900 01 01.

Urate as a predictor of the rate of clinical decline in Parkinson disease.

Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA,

Archives of neurology.. 2009 December 66 (12):1460-8. Epub 1900 01 01.

ADAGIO misses a beat?

Kieburtz K

The Lancet. Neurology.. 2009 December 8 (12):1081-2. Epub 1900 01 01.

A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.

Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I,

Movement disorders : official journal of the Movement Disorder Society.. 2009 October 3024 (14):2081-90. Epub 1900 01 01.

Using global statistical tests in long-term Parkinson's disease clinical trials.

Huang P, Goetz CG, Woolson RF, Tilley B, Kerr D, Palesch Y, Elm J, Ravina B, Bergmann KJ, Kieburtz K,

Movement disorders : official journal of the Movement Disorder Society.. 2009 September 1524 (12):1732-9. Epub 1900 01 01.

The Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC).

Kupersmith MJ, Miller N, Balcer L, Gordon L, Wall M, Keltner J, Friedman D, Feldon S, McDermott M, Kieburtz K

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.. 2009 September 29 (3):259-61. Epub 1900 01 01.

Pivotal studies of orphan drugs approved for neurological diseases.

Mitsumoto J, Dorsey ER, Beck CA, Kieburtz K, Griggs RC

Annals of neurology.. 2009 August 66 (2):184-90. Epub 1900 01 01.

A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster.

Dworkin RH, Barbano RL, Tyring SK, Betts RF, McDermott MP, Pennella-Vaughan J, Bennett GJ, Berber E, Gnann JW, Irvine C, Kamp C, Kieburtz K, Max MB, Schmader KE

Pain.. 2009 April 142 (3):209-217. Epub 02/04/2009.

Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease.

Constantinescu R, Romer M, Oakes D, Rosengren L, Kieburtz K

Parkinsonism & related disorders.. 2009 March 15 (3):245-8. Epub 12/04/2008.

Effect of L-methionine on hot flashes in postmenopausal women: a randomized controlled trial.

Guttuso T, McDermott MP, Ng P, Kieburtz K

Menopause : the journal of the North American Menopause Society.. 2009 16 (5):1004-8. Epub 1900 01 01.

An approach to evaluating the therapeutic misconception.

Kim SY, Schrock L, Wilson RM, Frank SA, Holloway RG, Kieburtz K, de Vries RG

IRB.. 2009 31 (5):7-14. Epub 1900 01 01.

Trust in early phase research: therapeutic optimism and protective pessimism.

Kim SY, Holloway RG, Frank S, Wilson R, Kieburtz K

Medicine, health care, and philosophy.. 2008 December 11 (4):393-401. Epub 07/16/2008.

Why have we failed to achieve neuroprotection in Parkinson's disease?

Olanow CW, Kieburtz K, Schapira AH

Annals of neurology.. 2008 December 64 Suppl 2 :S101-10. Epub 1900 01 01.

Therapeutic strategies to prevent motor complications in Parkinson's disease.

Kieburtz K

Journal of neurology.. 2008 August 255 Suppl 4 :42-5. Epub 1900 01 01.

The relationship between CAG repeat length and clinical progression in Huntington's disease.

Ravina B, Romer M, Constantinescu R, Biglan K, Brocht A, Kieburtz K, Shoulson I, McDermott MP

Movement disorders : official journal of the Movement Disorder Society.. 2008 July 1523 (9):1223-7. Epub 1900 01 01.

Effects of L-isoleucine and L-valine on hot flushes and serum homocysteine: a randomized controlled trial.

Guttuso T, McDermott MP, Su H, Kieburtz K

Obstetrics and gynecology.. 2008 July 112 (1):109-15. Epub 1900 01 01.

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.

Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, , Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J

Archives of neurology.. 2008 June 65 (6):716-23. Epub 04/14/2008.

Ethics of sham surgery: perspective of patients.

Frank SA, Wilson R, Holloway RG, Zimmerman C, Peterson DR, Kieburtz K, Kim SY

Movement disorders : official journal of the Movement Disorder Society.. 2008 January 23 (1):63-8. Epub 1900 01 01.

A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone).

Constantinescu R, McDermott MP, Dicenzo R, de Blieck EA, Hyson HC, Beal MF, Bednarczyk EM, Bogdanov M, Metakis LJ, Browne SE, Lorenzo BJ, Ravina B, Kieburtz K

Journal of clinical pharmacology.. 2007 December 47 (12):1580-6. Epub 10/09/2007.

Impact of pramipexole on the onset of levodopa-related dyskinesias.

Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K,

Movement disorders : official journal of the Movement Disorder Society.. 2007 July 1522 (9):1317-9. Epub 1900 01 01.

Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease.

Johnson SA, Stout JC, Solomon AC, Langbehn DR, Aylward EH, Cruce CB, Ross CA, Nance M, Kayson E, Julian-Baros E, Hayden MR, Kieburtz K, Guttman M, Oakes D, Shoulson I, Beglinger L, Duff K, Penziner E, Paulsen JS,

Brain : a journal of neurology.. 2007 July 130 (Pt 7):1732-44. Epub 1900 01 01.

Why hasn't neuroprotection worked in Parkinson's disease?

Kieburtz K, Ravina B

Nature clinical practice. Neurology.. 2007 May 3 (5):240-1. Epub 1900 01 01.

Malignant melanoma in early Parkinson's disease: the DATATOP trial.

Constantinescu R, Romer M, Kieburtz K,

Movement disorders : official journal of the Movement Disorder Society.. 2007 April 1522 (5):720-2. Epub 1900 01 01.

Verbal episodic memory declines prior to diagnosis in Huntington's disease.

Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, Ross CA, Beglinger L, Hayden MR, Kieburtz K, Kayson E, Julian-Baros E, Duff K, Guttman M, Nance M, Oakes D, Shoulson I, Penziner E, Paulsen JS,

Neuropsychologia.. 2007 April 945 (8):1767-76. Epub 01/09/2007.

Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy.

Kieburtz K, Olanow CW

The Mount Sinai journal of medicine, New York.. 2007 April 74 (1):7-14. Epub 1900 01 01.

Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM

Neurology.. 2007 January 3068 (5):384-6. Epub 11/02/2006.

An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection.

Sevigny JJ, Albert SM, McDermott MP, Schifitto G, McArthur JC, Sacktor N, Conant K, Selnes OA, Stern Y, McClernon DR, Palumbo D, Kieburtz K, Riggs G, Cohen B, Marder K, Epstein LG

Archives of neurology.. 2007 January 64 (1):97-102. Epub 1900 01 01.

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.

Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, Pohlmann H, Hubble J

The Lancet. Neurology.. 2006 December 5 (12):1013-20. Epub 1900 01 01.

Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.

Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I, ,

Journal of the neurological sciences.. 2006 October 25248 (1-2):78-83. Epub 07/07/2006.

Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.

deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I, ,

Movement disorders : official journal of the Movement Disorder Society.. 2006 October 21 (10):1716-21. Epub 1900 01 01.

Prevalence of dementia in rural China: impact of age, gender and education.

Zhou DF, Wu CS, Qi H, Fan JH, Sun XD, Como P, Qiao YL, Zhang L, Kieburtz K

Acta neurologica Scandinavica.. 2006 October 114 (4):273-80. Epub 1900 01 01.

Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

Holford NH, Chan PL, Nutt JG, Kieburtz K, Shoulson I,

Journal of pharmacokinetics and pharmacodynamics.. 2006 June 33 (3):281-311. Epub 04/20/2006.

Preparing for preventive clinical trials: the Predict-HD study.

Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E,

Archives of neurology.. 2006 June 63 (6):883-90. Epub 1900 01 01.

Issues in neuroprotection clinical trials in Parkinson's disease.

Kieburtz K

Neurology.. 2006 May 2366 (10 Suppl 4):S50-7. Epub 1900 01 01.

Appointing a proxy for research consent after one develops dementia: the need for further study.

Kim SY, Kieburtz K

Neurology.. 2006 May 966 (9):1298-9. Epub 1900 01 01.

Rasagiline improves quality of life in patients with early Parkinson's disease.

Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I,

Movement disorders : official journal of the Movement Disorder Society.. 2006 May 21 (5):616-23. Epub 1900 01 01.

Volunteering for early phase gene transfer research in Parkinson disease.

Kim SY, Holloway RG, Frank S, Beck CA, Zimmerman C, Wilson R, Kieburtz K

Neurology.. 2006 April 1166 (7):1010-5. Epub 03/15/2006.

Dietary factors and smoking as risk factors for PD in a rural population in China: a nested case-control study.

Ma L, Zhang L, Gao XH, Chen W, Wu YP, Wang Y, Li XF, Como P, Kieburtz K, Qiao YL

Acta neurologica Scandinavica.. 2006 April 113 (4):278-81. Epub 1900 01 01.

Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.

Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, Shannon K, Wooten GF, Tanner CM, Goetz GC,

Neurology.. 2006 March 1466 (5):628-33. Epub 1900 01 01.

A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.

Blindauer K, Shoulson I, Oakes D, Kieburtz K, Schwid S, Fahn S, Stern M, Goetz C, Nutt J, Goren S, Sayag N, Scolnik M, Levy R, Eyal E, Salzman P, Pagano M,

Archives of neurology.. 2006 February 63 (2):210-6. Epub 1900 01 01.

What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports.

Frank S, Kieburtz K, Holloway R, Kim SY

Neurology.. 2005 October 1165 (7):1101-3. Epub 07/20/2005.

Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers.

Kim SY, Frank S, Holloway R, Zimmerman C, Wilson R, Kieburtz K

Archives of neurology.. 2005 September 62 (9):1357-60. Epub 1900 01 01.

High-dosage vitamin E supplementation and all-cause mortality.

Marras C, Lang AE, Oakes D, McDermott MP, Kieburtz K, Shoulson I, Tanner CM, Fahn S

Annals of internal medicine.. 2005 July 19143 (2):152-3; author reply 156-8. Epub 1900 01 01.

The prevalence of PD in a nutritionally deficient rural population in China.

Zhang L, Nie ZY, Liu Y, Chen W, Xin SM, Sun XD, Fan JH, Liu YH, Gao XH, Lu LQ, Como P, McDermott MP, Qiao YL, Kieburtz K

Acta neurologica Scandinavica.. 2005 July 112 (1):29-35. Epub 1900 01 01.

Welding and Parkinson disease: is there a bond?

Kieburtz K, Kurlan R

Neurology.. 2005 June 2864 (12):2001-3. Epub 1900 01 01.

Markers of immune activation and viral load in HIV-associated sensory neuropathy.

Schifitto G, McDermott MP, McArthur JC, Marder K, Sacktor N, McClernon DR, Conant K, Cohen B, Epstein LG, Kieburtz K,

Neurology.. 2005 March 864 (5):842-8. Epub 1900 01 01.

Interrater agreement in the assessment of motor manifestations of Huntington's disease.

Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, Shoulson I, Wexler NS, Young AB, Zhao H

Movement disorders : official journal of the Movement Disorder Society.. 2005 March 20 (3):293-7. Epub 1900 01 01.

A responsive outcome for Parkinson's disease neuroprotection futility studies.

Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K,

Annals of neurology.. 2005 February 57 (2):197-203. Epub 1900 01 01.

The role of radiotracer imaging in Parkinson disease.

Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, Dhawan V, Feigin A, Fahn S, Guttman M, Gwinn-Hardy K, McFarland H, Innis R, Katz RG, Kieburtz K, Kish SJ, Lange N, Langston JW, Marek K, Morin L, Moy C, Murphy D, Oertel WH, Oliver G, Palesch Y, Powers W, Seibyl J, Sethi KD, Shults CW, Sheehy P, Stoessl AJ, Holloway R

Neurology.. 2005 January 2564 (2):208-15. Epub 1900 01 01.

Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials.

Guimaraes P, Kieburtz K, Goetz CG, Elm JJ, Palesch YY, Huang P, Ravina B, Tanner CM, Tilley BC

Clinical trials : journal of the Society for Clinical Trials.. 2005 2 (6):509-18. Epub 1900 01 01.

Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia.

Sevigny JJ, Albert SM, McDermott MP, McArthur JC, Sacktor N, Conant K, Schifitto G, Selnes OA, Stern Y, McClernon DR, Palumbo D, Kieburtz K, Riggs G, Cohen B, Epstein LG, Marder K

Neurology.. 2004 December 1463 (11):2084-90. Epub 1900 01 01.

Levodopa and the progression of Parkinson's disease.

Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K,

The New England journal of medicine.. 2004 December 9351 (24):2498-508. Epub 1900 01 01.

Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy.

McArthur JC, McDermott MP, McClernon D, St Hillaire C, Conant K, Marder K, Schifitto G, Selnes OA, Sacktor N, Stern Y, Albert SM, Kieburtz K, deMarcaida JA, Cohen B, Epstein LG

Archives of neurology.. 2004 November 61 (11):1687-96. Epub 1900 01 01.

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.

Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J,

Archives of neurology.. 2004 October 61 (10):1563-8. Epub 1900 01 01.

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A,

Archives of neurology.. 2004 July 61 (7):1044-53. Epub 1900 01 01.

Measuring the effects of therapy in Parkinson disease.

Shults CW, Haas R, Oakes D, Kieburtz K, Plumb S, Shoulson I, Beal MF, Juncos J, Nutt J

JAMA.. 2004 May 26291 (20):2430-1; author reply 2431. Epub 1900 01 01.

Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study.

Aylward EH, Rosenblatt A, Field K, Yallapragada V, Kieburtz K, McDermott M, Raymond LA, Almqvist EW, Hayden M, Ross CA

Brain research bulletin.. 2003 December 1562 (2):137-41. Epub 1900 01 01.

Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment.

Marder K, Albert SM, McDermott MP, McArthur JC, Schifitto G, Selnes OA, Sacktor N, Stern Y, Palumbo D, Kieburtz K, Cohen B, Orme C, Epstein LG

Neurology.. 2003 May 1360 (9):1467-73. Epub 1900 01 01.

Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial.

Guttuso T, Kurlan R, McDermott MP, Kieburtz K

Obstetrics and gynecology.. 2003 February 101 (2):337-45. Epub 1900 01 01.

Designing neuroprotection trials in Parkinson's disease.

Kieburtz K

Annals of neurology.. 2003 53 Suppl 3 :S100-7; discussion S107-9. Epub 1900 01 01.

Needed in MS: evidence, not EVIDENCE.

Kieburtz K, McDermott M

Neurology.. 2002 November 2659 (10):1482-3. Epub 1900 01 01.

A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment.

Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, Letendre S, Cohen BA, Marder K, Ellis RJ, Marra CM,

Neurology.. 2002 November 2659 (10):1568-73. Epub 1900 01 01.

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.

Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M,

Archives of neurology.. 2002 October 59 (10):1541-50. Epub 1900 01 01.

Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.

Siderowf A, McDermott M, Kieburtz K, Blindauer K, Plumb S, Shoulson I,

Movement disorders : official journal of the Movement Disorder Society.. 2002 July 17 (4):758-63. Epub 1900 01 01.

Incidence of and risk factors for HIV-associated distal sensory polyneuropathy.

Schifitto G, McDermott MP, McArthur JC, Marder K, Sacktor N, Epstein L, Kieburtz K,

Neurology.. 2002 June 2558 (12):1764-8. Epub 1900 01 01.

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.

Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A,

Annals of neurology.. 2002 May 51 (5):604-12. Epub 1900 01 01.

HIV-associated cognitive impairment before and after the advent of combination therapy.

Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L

Journal of neurovirology.. 2002 April 8 (2):136-42. Epub 1900 01 01.

Factors associated with incident human immunodeficiency virus-dementia.

Stern Y, McDermott MP, Albert S, Palumbo D, Selnes OA, McArthur J, Sacktor N, Schifitto G, Kieburtz K, Epstein L, Marder KS,

Archives of neurology.. 2001 March 58 (3):473-9. Epub 1900 01 01.

Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes.

Schifitto G, Kieburtz K, McDermott MP, McArthur J, Marder K, Sacktor N, Palumbo D, Selnes O, Stern Y, Epstein L, Albert S

Neurology.. 2001 February 1356 (3):415-8. Epub 1900 01 01.

Message from the editors to our ad hoc reviewers.

Griggs RC, Kieburtz KD, Duffy CJ, McDermott MP

Neurology.. 2000 December 2655 (12):1766-9. Epub 1900 01 01.

Autonomic performance and dehydroepiandrosterone sulfate levels in HIV-1-infected individuals: relationship to TH1 and TH2 cytokine profile.

Schifitto G, McDermott MP, Evans T, Fitzgerald T, Schwimmer J, Demeter L, Kieburtz K

Archives of neurology.. 2000 July 57 (7):1027-32. Epub 1900 01 01.

Of mice and men: a model of HIV encephalitis.

McArthur JC, Kieburtz K

Neurology.. 2000 January 2554 (2):284-5. Epub 1900 01 01.

Rate of functional decline in Huntington's disease. Huntington Study Group.

Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I

Neurology.. 2000 January 2554 (2):452-8. Epub 1900 01 01.

Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.

Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K

Neurology.. 2000 January 1154 (1):233-5. Epub 1900 01 01.

Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials.

Kieburtz K, Hubble J

Neurology.. 2000 55 (11 Suppl 4):S42-5; discussion S46-50. Epub 1900 01 01.

Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium.

Schifitto G, Sacktor N, Marder K, McDermott MP, McArthur JC, Kieburtz K, Small S, Epstein LG

Neurology.. 1999 July 2253 (2):391-6. Epub 1900 01 01.

Antiglutamate therapies in Huntington's disease.

Kieburtz K

Journal of neural transmission. Supplementum.. 1999 55 :97-102. Epub 1900 01 01.

The placebo response in Parkinson's disease. Parkinson Study Group.

Shetty N, Friedman JH, Kieburtz K, Marshall FJ, Oakes D

Clinical neuropharmacology.. 1999 22 (4):207-12. Epub 1900 01 01.

Avoiding conflicts of interest: responsibilities of authors, reviewers, and editors.

Kieburtz K

Neurology.. 1998 December 51 (6):1527-8. Epub 1900 01 01.

A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team.

Kieburtz K, Simpson D, Yiannoutsos C, Max MB, Hall CD, Ellis RJ, Marra CM, McKendall R, Singer E, Dal Pan GJ, Clifford DB, Tucker T, Cohen B

Neurology.. 1998 December 51 (6):1682-8. Epub 1900 01 01.

Unified Huntington's disease rating scale: a follow up.

Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA

Movement disorders : official journal of the Movement Disorder Society.. 1998 November 13 (6):915-9. Epub 1900 01 01.

Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.

Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH

Neurology.. 1998 May 50 (5):1327-31. Epub 1900 01 01.

HIV related vasculitic mononeuropathy multiplex: a role for IVIg?

Schifitto G, Barbano RL, Kieburtz KD, Cohn SE, Zwillich SH

Journal of neurology, neurosurgery, and psychiatry.. 1997 August 63 (2):255-6. Epub 1900 01 01.

Policies on reporting clinical trials and publishing supplements.

Kieburtz K

Neurology.. 1997 July 49 (1):2-3. Epub 1900 01 01.

Stable neurological function in subjects treated with 2'3'-dideoxyinosine.

Sidtis JJ, Dafni U, Slasor P, Hall C, Price RW, Kieburtz K, Tucker T, Clifford DB

Journal of neurovirology.. 1997 June 3 (3):233-40. Epub 1900 01 01.

A shortened version of the motor section of the Unified Huntington's Disease Rating Scale.

Siesling S, Zwinderman AH, van Vugt JP, Kieburtz K, Roos RA

Movement disorders : official journal of the Movement Disorder Society.. 1997 March 12 (2):229-34. Epub 1900 01 01.

CNS lymphoma in an AIDS patient involving the posterior fornix case report.

Ketonen L, Kieburtz KD, Tuite MJ, Eskin T, Simon J

Journal of neuro-AIDS.. 1997 1 (3):43-9. Epub 1900 01 01.

A controlled trial of remacemide hydrochloride in Huntington's disease.

Kieburtz K, Feigin A, McDermott M, Como P, Abwender D, Zimmerman C, Hickey C, Orme C, Claude K, Sotack J, Greenamyre JT, Dunn C, Shoulson I

Movement disorders : official journal of the Movement Disorder Society.. 1996 May 11 (3):273-7. Epub 1900 01 01.

Assessment of coenzyme Q10 tolerability in Huntington's disease.

Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, Shoulson I

Movement disorders : official journal of the Movement Disorder Society.. 1996 May 11 (3):321-3. Epub 1900 01 01.

Clinical research in neurology. From observation to experimentation.

Marshall FJ, Kieburtz K, McDermott M, Kurlan R, Shoulson I

Neurologic clinics.. 1996 May 14 (2):451-66. Epub 1900 01 01.

Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD).

Quinn N, Brown R, Craufurd D, Goldman S, Hodges J, Kieburtz K, Lindvall O, MacMillan J, Roos R

Movement disorders : official journal of the Movement Disorder Society.. 1996 March 11 (2):143-50. Epub 1900 01 01.

Cognitive performance and regional brain volume in human immunodeficiency virus type 1 infection.

Kieburtz K, Ketonen L, Cox C, Grossman H, Holloway R, Booth H, Hickey C, Feigin A, Caine ED

Archives of neurology.. 1996 February 53 (2):155-8. Epub 1900 01 01.

Putaminal Iron Deposition<br />in HIV Infection.

Ketonen L, Kieburtz K, Kazee AM, Tuite M

Journal of neuro-AIDS.. 1996 1 (2):33-40. Epub 1900 01 01.

Pilot Study of Didanosine in Patients with HIV Dementia.

Kieburtz KD, Price RW, Sidtis JJ, Hall C, Grundman M, McLaren C

Journal of neuro-AIDS.. 1996 1 (4):1-5. Epub 1900 01 01.

Headache and the human immunodeficiency virus type 1 infection.

Holloway RG, Kieburtz KD

Headache.. 1995 May 35 (5):245-55. Epub 1900 01 01.

Functional decline in Huntington's disease.

Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, Zimmerman C, Hickey C, Orme C, Shoulson I

Movement disorders : official journal of the Movement Disorder Society.. 1995 March 10 (2):211-4. Epub 1900 01 01.

Trinucleotide repeat length and progression of illness in Huntington's disease.

Kieburtz K, MacDonald M, Shih C, Feigin A, Steinberg K, Bordwell K, Zimmerman C, Srinidhi J, Sotack J, Gusella J

Journal of medical genetics.. 1994 November 31 (11):872-4. Epub 1900 01 01.

The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.

Kieburtz K, McDermott M, Como P, Growdon J, Brady J, Carter J, Huber S, Kanigan B, Landow E, Rudolph A

Neurology.. 1994 September 44 (9):1756-9. Epub 1900 01 01.

HIV or zidovudine myopathy?

Kieburtz K

Neurology.. 1994 February 44 (2):361; author reply 362-4. Epub 1900 01 01.

Opportunistic cerebral vasculopathy and stroke in patients with the acquired immunodeficiency syndrome.

Kieburtz KD, Eskin TA, Ketonen L, Tuite MJ

Archives of neurology.. 1993 April 50 (4):430-2. Epub 1900 01 01.

Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group.

Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, Richman DD, Hirsch MS, Schaerf FW, Fischl MA, Kieburtz K

Annals of neurology.. 1993 April 33 (4):343-9. Epub 1900 01 01.

Efficacy of gadolinium in MR brain imaging of HIV-infected patients.

Tuite M, Ketonen L, Kieburtz K, Handy B

AJNR. American journal of neuroradiology.. 1993 14 (1):257-63. Epub 1900 01 01.

Cerebrovascular complications after primary varicella-zoster infection.

Schwid S, Ketonen L, Betts R, Richfield E, Kieburtz K

Lancet.. 1992 September 12340 (8820):669. Epub 1900 01 01.

Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine.

Kieburtz KD, Seidlin M, Lambert JS, Dolin R, Reichman R, Valentine F

Journal of acquired immune deficiency syndromes.. 1992 5 (1):60-4. Epub 1900 01 01.

Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications.

Kieburtz KD, Epstein LG, Gelbard HA, Greenamyre JT

Archives of neurology.. 1991 December 48 (12):1281-4. Epub 1900 01 01.

Manic syndrome in AIDS.

Kieburtz K, Zettelmaier AE, Ketonen L, Tuite M, Caine ED

The American journal of psychiatry.. 1991 August 148 (8):1068-70. Epub 1900 01 01.

Abnormal vitamin B12 metabolism in human immunodeficiency virus infection. Association with neurological dysfunction.

Kieburtz KD, Giang DW, Schiffer RB, Vakil N

Archives of neurology.. 1991 March 48 (3):312-4. Epub 1900 01 01.

Chemical-shift imaging of a spontaneous internal carotid artery dissection: case report.

Pacini R, Simon J, Ketonen L, Kido D, Kieburtz K

AJNR. American journal of neuroradiology.. 1991 12 (2):360-2. Epub 1900 01 01.

Magnetic resonance imaging findings in HIV cognitive impairment.

Kieburtz KD, Ketonen L, Zettelmaier AE, Kido D, Caine ED, Simon JH

Archives of neurology.. 1990 June 47 (6):643-5. Epub 1900 01 01.

Seizures following carotid endarterectomy.

Kieburtz K, Ricotta JJ, Moxley RT

Archives of neurology.. 1990 May 47 (5):568-70. Epub 1900 01 01.

Neurologic manifestations of human immunodeficiency virus infections.

Kieburtz K, Schiffer RB

Neurologic clinics.. 1989 August 7 (3):447-68. Epub 1900 01 01.

Variation in individual physicians' prescribing.

Johnson RE, Azevedo DJ, Kieburtz KD

The Journal of ambulatory care management.. 1986 February 9 (1):25-37. Epub 1900 01 01.

Prescribing rate of internists in an HMO and the influence of information sources.

Kieburtz KD, Johnson RE

GHAA journal.. 1986 7 (1):60-71. Epub 1900 01 01.

Locations

UR Medicine Neurology

919 Westfall Rd, Bldg. C, Suite 100
Rochester, NY 14618

(585) 341-7500 Get Directions